NEW YORK (GenomeWeb News) – Genomic Health reported after the close of the market on Wednesday that its third-quarter revenues rose 41 percent on increased sales of its Oncotype Dx breast cancer test.

The Redwood City, Calif.-based firm brought in total revenues of $39.5 million for the three-month period ended Sept. 30, up from $28.1 million the year before. Its product sales, which came exclusively from the sale of the Oncotype Dx test, rose 39 percent year over year to $38.9 million from $28.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Helix customers can purchase apps that interpret different aspects of their genome, Technology Review reports.

The New York Times reports that a number of companies and research institutes are pursuing gene therapies.

Salmon with shorter telomeres survive to make the trip back to their river homes, New Scientist reports.

In PLOS this week: vaginal microbiome composition, population patterns of Chagas-carrying Rhodnius ecuadoriensis, and more.